Table 2 Patient characteristics, comorbidities and outcome
AKI (N = 10) | NO AKI (N = 9) | |
|---|---|---|
Age, years [IQR] | 66 [64–72] | 65 [53–70] |
Male, n (%) | 8 (80%) | 8 (89%) |
Height, cm [IQR] | 173 [169–177] | 180 [170–187] |
Weight, kg [IQR] | 94 [82–102] | 86 [80–102] |
Body Mass Index, [IQR] | 32 [27–35] | 27 [26–36] |
Hypertension, n (%) | 7 (70%) | 5 (56%) |
History of treatment with ARB/ACEi, n (%) | 7 (70%) | 6 (67%) |
Diabetes, n (%) | 4 (40%) | 2 (22%) |
Ischemic heart disease or congestive heart failure, n (%) | 3 (30%) | 2 (22%) |
Ischemic heart disease, n (%) | 3 (30%) | 1 (11%) |
Congestive heart failure, n (%) | 0 (0%) | 1 (11%) |
Asthma or COPD, n (%) | 2 (20%) | 0 (0%) |
History of CKD, n (%) | 0 (0%) | 0 (0%) |
Baseline Plasma-Creatinine, µmol/l [IQR] | 68 [65–77] | 66 [58–73] |
Most severe AKI stage during hospital stay, [IQR] | 2 [2, 3] | 0[0–1] |
AKI stage 2 or 3 any time during hospital stay, n (%) | 8 (80%) | 0 (0%) |
RRT at any time in ICU, n (%) | 2 (20%) | 0 (0%) |
SAPS 3, [IQR] | 54 [52–56] | 53 [50–55] |
Days of symptomatic COVID-19 at ICU-admission, [IQR] | 9 [8–11] | 9 [9, 10] |
Treatment with dexametasone, n (%) | 8 (80%) | 7 (78%) |
IMV at any time during ICU stay, n (%) | 10 (100%) | 7 (78%) |
Days with IMV, [IQR] | 18 [15–22] | 14 [6–18] |
Vasoactive treatment at any time in ICU, n (%) | 10 (100%) | 7 (78%) |
Moderate or severe ARDS, n (%) | 10 (100%) | 8 (89%) |
Severe ARDS, n (%) | 8 (80%) | 5 (56%) |
90-day survival, n (%) | 6 (60%) | 6 (67%) |